Patent ID: 9623025
Date: 2017-04-18
CPC Classifications: A61K,A61P

Claim:
1. A method of inhibiting alpha-carbonic anhydrase isoforms in a mammal having a disorder mediated by alpha-carbonic anhydrase isoforms, the method comprising administering to the mammal having a disorder mediated by alpha-carbonic anhydrase isoforms, an effective amount of 4-(4-methylpiperazin- 1-ylmethyl)-N-[4-methyl-3 -(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-b enzamide or a pharmaceutically acceptable salt thereof, or 4-methyl-3-[[4-(3-pyridinyl)-2-pyri midinyl] amino] -N-[5-(4-methyl- 1H-imidazol- 1-yl)-3-(trifluoromethyl)phenyl] benzamide or a pharmaceutically acceptable salt thereof, the disorder being selected from the group consisting of intraocular hypertension (glaucoma), epilepsy, Lennox-Gastaut syndrome, altitude sickness, headaches, neurological disorders, and obesity.